Authors


Adam Friedman, MD, FAAD

Latest:

Adam Friedman, MD, FAAD: Exploring the Utilization of Immunomodulators as Therapeutic Interventions in Chronic Spontaneous Urticaria

In addition to recapping key highlights from his session, Friedman discusses what is new or upcoming in dermatology that most excites him.


Tristan Hasbargen, PA-C

Latest:

Tristan Hasbargen, PA-C: Closure Types in Mohs Surgery and More

Hasbargen presented Mohs surgery pearls on closure types and pattern recognition at the 2024 Diversity in Dermatology meeting.


Nicole Vélez, MD, FACMS

Latest:

Grow Your Practice With the Right Marketing and SEO

Nicole Vélez, MD, provided marketing pearls to streamline mundane tasks and promote your practice in the digital world.



Roy M. Fleischmann, MD

Latest:

Addressing Patients' Concerns With Biosimilars

Drs Roy M. Fleischmann and Joel M. Gelfand discuss addressing patient concerns with biosimilars and provide take-home messages to clinicians utilizing biosimilars.


Gabrielle Ientile

Latest:

2021 Acne Updates: New Drugs and Research

A presentation from Maui Derm Live 2021 featured insights on new drugs and data in acne.



Anthony J. Mancini, MD, FAAP, FAAD

Latest:

Q&A: Diagnostic and Therapeutic Pearls for Pediatric Dermatology

Mancini discusses his SPD 2024 lecture, emphasizing off-label treatments, surrogate diagnostic markers, simpler therapies, and the importance of empathy and education.



Rashmi Sarkar, MD, FAMS

Latest:

Rashmi Sarkar, MD, FAMS: Vitiligo and Stigma

Sarkar spoke with Dermatology Times after the ReV conference to discuss her session on vitiligo stigma.


Dorothy McCabe, PhD, FCP

Latest:

Cyltezo Biosimilar Launches Today in the US

Boehringer Ingelheim’s Cyltezo is the first and only FDA-approved interchangeable biosimilar to adalimumab.


Fred Gebhart

Latest:

The JAK Inhibitor Pipeline Builds in Dermatology

Eight JAK inhibitors are approved by the FDA to treat autoimmune, inflammatory, and allergic conditions.


Michael Kahn, PhD

Latest:

CBP/β-catenin Antagonists: A Safe and Novel Approach for Skin Rejuvenation and Aging

Take a look at this overview of the top 5 considerations to show how CBP/β-catenin antagonists can be utilized for skin rejuvenation and anti-aging by enhancing Wnt/p300/β-catenin transcription.


Janet Dyer

Latest:

Further Research Needed to Study Link Between AD and ADHD

Researchers found an association between ADHD and three inflammatory conditions—atopic dermatitis, otitis media, and herpes simplex infection.


Jennifer Soung, MD

Latest:

Roflumilast Patient Selection for Plaque Psoriasis Treatment

Experts describe roflumilast patient selection for plaque psoriasis treatment.


Ryan Scott

Latest:

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.


Thomas J. Knackstedt, MD, MPH, FACMS

Latest:

Looking Ahead to the 2023 ACMS Meeting

The ACMS president and scientific program chair share opportunities to discover innovations in Mohs surgery during this weekend’s meeting.


Antonia DePace

Latest:

Gut Microbiome Can Affect Radiation Cancer Treatment

The overgrowth of fungi could cause the immune system to stop fighting cancer, according to a study.


Andrew F. Alexis, MD, MPH

Latest:

Overcoming Treatment Barriers in Vitiligo: From Insurance Coverage to Patient Adherence

Andrew Alexis, MD, MPH, reviews the case of a 66-year-old woman who presented with depigmented patches and provides clinical insights on barriers typically encountered during the management of this condition.


Robyn Siperstein, MD, FAAD

Latest:

Hands-on Workshop Empowers Clinicians in Cosmetic Dermatology

Robin Siperstein, MD, FAAD, shares practical tips in cosmetic dermatology at the 2024 SDPA Annual Summer Dermatology Meeting.


Jeffrey Cohen, MD

Latest:

Key Takeaways on the Management of Atopic Dermatitis

Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.


Zakiya Pressley Rice, MD

Latest:

Addressing Quality of Life Specifics Associated With Atopic Dermatitis and Skin of Color

Zakiya Pressley Rice, MD, took a deep dive into how atopic dermatitis severity and increased rates of grade school absenteeism affect patients with skin of color during a recent Masterclasses in Dermatology meeting.


Hannah Badon, MD

Latest:

Dermatologic differences in a diverse population

Understanding the difference in biology and clinical presentations of cutaneous conditions in different skin types is critical for health care professionals to treat a diverse population.


Lloyd Miller, MD, PhD

Latest:

Lloyd Miller, MD, PhD: Delving Into JNJ-2113 Data for Plaque Psoriasis

Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.



R. Caleb Kovell, MD

Latest:

The Importance of Collaboration Between Mohs Surgeons and Urologists

Caleb Kovell, MD and Junqian Zhang, MD demonstrated how teaming up increases the likelihood for positive patient outcomes in Mohs cases on the genitalia and perianal region.


Saakshi Khattri, MD

Latest:

Key Takeaways For the Management of Plaque Psoriasis

Experts in dermatology share closing thoughts on the management of plaque psoriasis.


Gina Battaglia, PhD, Correspondent

Latest:

Frontline Forum Part 4: Improving Basal Cell Carcinoma Management

In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.


Stefan Weiss, MD, MBA, FAAD

Latest:

SFA-002 Shows Promise in Early Clinical Trial Psoriasis Cohorts

Stefan Weiss, MD, MBA, explains next steps for the oral treatment after the completion of phase 1b enrollment.


Lauren Miller, MPAS, PA-C

Latest:

Deucravacitinib: A Year in Review

As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.

© 2024 MJH Life Sciences

All rights reserved.